561 related articles for article (PubMed ID: 23494446)
1. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
[TBL] [Abstract][Full Text] [Related]
2. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
5. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Raccah D; Gourdy P; Sagnard L; Ceriello A
Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
[TBL] [Abstract][Full Text] [Related]
6. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Monami M; Liistro F; Scatena A; Nreu B; Mannucci E
Diabetes Obes Metab; 2018 May; 20(5):1213-1222. PubMed ID: 29327406
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
8. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
11. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Onishi Y; Oura T; Nishiyama H; Ohyama S; Takeuchi M; Iwamoto N
Endocr J; 2016; 63(3):263-73. PubMed ID: 26698689
[TBL] [Abstract][Full Text] [Related]
12. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
13. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
[TBL] [Abstract][Full Text] [Related]
15. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
[TBL] [Abstract][Full Text] [Related]
18. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
Zhou JB; Bai L; Wang Y; Yang JK
Int J Clin Pract; 2016 Feb; 70(2):132-41. PubMed ID: 26709610
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Chan SP; Colagiuri S
Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
[TBL] [Abstract][Full Text] [Related]
20. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]